nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—Cytochrome P450 3A4 Inhibitors—Cyclosporine—focal segmental glomerulosclerosis	0.776	1	CiPCiCtD
Atazanavir—ABCC1—Cyclosporine—focal segmental glomerulosclerosis	0.114	0.612	CbGbCtD
Atazanavir—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0283	0.152	CbGbCtD
Atazanavir—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0275	0.148	CbGbCtD
Atazanavir—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0165	0.0884	CbGbCtD
Atazanavir—Atrophy—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.0422	CcSEcCtD
Atazanavir—Urine abnormality—Cyclosporine—focal segmental glomerulosclerosis	0.000941	0.0248	CcSEcCtD
Atazanavir—Hypertriglyceridaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000907	0.0239	CcSEcCtD
Atazanavir—Urine analysis abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000886	0.0234	CcSEcCtD
Atazanavir—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000803	0.0212	CcSEcCtD
Atazanavir—Blood triglycerides increased—Cyclosporine—focal segmental glomerulosclerosis	0.000795	0.021	CcSEcCtD
Atazanavir—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.000779	0.0206	CcSEcCtD
Atazanavir—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000764	0.0202	CcSEcCtD
Atazanavir—Burning sensation—Cyclosporine—focal segmental glomerulosclerosis	0.00075	0.0198	CcSEcCtD
Atazanavir—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000743	0.0196	CcSEcCtD
Atazanavir—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.000686	0.0181	CcSEcCtD
Atazanavir—Liver injury—Cyclosporine—focal segmental glomerulosclerosis	0.000619	0.0163	CcSEcCtD
Atazanavir—Amenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000593	0.0156	CcSEcCtD
Atazanavir—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.000573	0.0151	CcSEcCtD
Atazanavir—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000573	0.0151	CcSEcCtD
Atazanavir—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.0147	CcSEcCtD
Atazanavir—Hiccups—Cyclosporine—focal segmental glomerulosclerosis	0.000521	0.0138	CcSEcCtD
Atazanavir—Hepatocellular injury—Cyclosporine—focal segmental glomerulosclerosis	0.000521	0.0138	CcSEcCtD
Atazanavir—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.000494	0.0131	CcSEcCtD
Atazanavir—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.000476	0.0126	CcSEcCtD
Atazanavir—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.000471	0.0124	CcSEcCtD
Atazanavir—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.000466	0.0123	CcSEcCtD
Atazanavir—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.000435	0.0115	CcSEcCtD
Atazanavir—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.000431	0.0114	CcSEcCtD
Atazanavir—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.000427	0.0113	CcSEcCtD
Atazanavir—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.0112	CcSEcCtD
Atazanavir—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.0112	CcSEcCtD
Atazanavir—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.000421	0.0111	CcSEcCtD
Atazanavir—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000408	0.0108	CcSEcCtD
Atazanavir—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000402	0.0106	CcSEcCtD
Atazanavir—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.000396	0.0104	CcSEcCtD
Atazanavir—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000392	0.0104	CcSEcCtD
Atazanavir—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000387	0.0102	CcSEcCtD
Atazanavir—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.000375	0.0099	CcSEcCtD
Atazanavir—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.000372	0.00982	CcSEcCtD
Atazanavir—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.000358	0.00946	CcSEcCtD
Atazanavir—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000347	0.00915	CcSEcCtD
Atazanavir—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000342	0.00902	CcSEcCtD
Atazanavir—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000335	0.00883	CcSEcCtD
Atazanavir—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000333	0.0088	CcSEcCtD
Atazanavir—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000329	0.00868	CcSEcCtD
Atazanavir—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00032	0.00846	CcSEcCtD
Atazanavir—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000302	0.00797	CcSEcCtD
Atazanavir—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000297	0.00785	CcSEcCtD
Atazanavir—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000296	0.0078	CcSEcCtD
Atazanavir—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000295	0.00778	CcSEcCtD
Atazanavir—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00029	0.00767	CcSEcCtD
Atazanavir—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000286	0.00756	CcSEcCtD
Atazanavir—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000286	0.00754	CcSEcCtD
Atazanavir—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000284	0.0075	CcSEcCtD
Atazanavir—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000284	0.0075	CcSEcCtD
Atazanavir—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000283	0.00748	CcSEcCtD
Atazanavir—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000278	0.00733	CcSEcCtD
Atazanavir—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000276	0.00727	CcSEcCtD
Atazanavir—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000262	0.00691	CcSEcCtD
Atazanavir—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00026	0.00687	CcSEcCtD
Atazanavir—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000258	0.00682	CcSEcCtD
Atazanavir—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000257	0.00679	CcSEcCtD
Atazanavir—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000256	0.00677	CcSEcCtD
Atazanavir—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000244	0.00644	CcSEcCtD
Atazanavir—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000237	0.00626	CcSEcCtD
Atazanavir—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000236	0.00622	CcSEcCtD
Atazanavir—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000231	0.0061	CcSEcCtD
Atazanavir—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000229	0.00605	CcSEcCtD
Atazanavir—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000228	0.00601	CcSEcCtD
Atazanavir—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000224	0.00592	CcSEcCtD
Atazanavir—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000223	0.0059	CcSEcCtD
Atazanavir—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000223	0.00589	CcSEcCtD
Atazanavir—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.000221	0.00584	CcSEcCtD
Atazanavir—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000211	0.00558	CcSEcCtD
Atazanavir—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.000209	0.00552	CcSEcCtD
Atazanavir—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000208	0.00549	CcSEcCtD
Atazanavir—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000205	0.00542	CcSEcCtD
Atazanavir—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000199	0.00525	CcSEcCtD
Atazanavir—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000197	0.00521	CcSEcCtD
Atazanavir—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000197	0.00519	CcSEcCtD
Atazanavir—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000194	0.00512	CcSEcCtD
Atazanavir—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000194	0.00512	CcSEcCtD
Atazanavir—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000194	0.00512	CcSEcCtD
Atazanavir—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000193	0.0051	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000192	0.00508	CcSEcCtD
Atazanavir—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000192	0.00506	CcSEcCtD
Atazanavir—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00019	0.005	CcSEcCtD
Atazanavir—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000187	0.00495	CcSEcCtD
Atazanavir—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000186	0.00491	CcSEcCtD
Atazanavir—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000185	0.00487	CcSEcCtD
Atazanavir—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000182	0.00481	CcSEcCtD
Atazanavir—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00018	0.00477	CcSEcCtD
Atazanavir—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00018	0.00474	CcSEcCtD
Atazanavir—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000177	0.00468	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00447	CcSEcCtD
Atazanavir—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00444	CcSEcCtD
Atazanavir—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000166	0.00437	CcSEcCtD
Atazanavir—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000165	0.00436	CcSEcCtD
Atazanavir—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000164	0.00432	CcSEcCtD
Atazanavir—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000162	0.00426	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00016	0.00424	CcSEcCtD
Atazanavir—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00016	0.00423	CcSEcCtD
Atazanavir—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000159	0.0042	CcSEcCtD
Atazanavir—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000159	0.0042	CcSEcCtD
Atazanavir—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000153	0.00404	CcSEcCtD
Atazanavir—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000152	0.00401	CcSEcCtD
Atazanavir—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000148	0.0039	CcSEcCtD
Atazanavir—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000147	0.00388	CcSEcCtD
Atazanavir—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000147	0.00388	CcSEcCtD
Atazanavir—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000137	0.00361	CcSEcCtD
Atazanavir—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000133	0.00352	CcSEcCtD
Atazanavir—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000131	0.00347	CcSEcCtD
Atazanavir—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000127	0.00336	CcSEcCtD
Atazanavir—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000123	0.00324	CcSEcCtD
Atazanavir—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000118	0.00312	CcSEcCtD
Atazanavir—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000117	0.00309	CcSEcCtD
Atazanavir—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000117	0.00309	CcSEcCtD
Atazanavir—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000116	0.00307	CcSEcCtD
Atazanavir—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00011	0.00291	CcSEcCtD
Atazanavir—Saquinavir—ALB—focal segmental glomerulosclerosis	3.03e-05	1	CrCbGaD
